Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind specifically to BlyS, immunoglobulin chains thereof, variants thereof; and method of use thereof, e.g., for the treatment or prevention of inflammatory and/or immune diseases such as systemic lupus erythramatous; as well as polynucleotides encoding the immunoglobulin chains of such antibodies and fragments. Methods for the recombinant expression of immunoglobulin chains are also part of the present invention.

Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.

Abstract: The present invention provides human anti-IL-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to IL-6 and that has an extended in vivo half-life for the treatment and prevention of IL-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors.

Abstract: The present disclosure relates to a nucleotide sequence comprising the sequence of SEQ ID NO: 5, and/or sequence of SEQ ID NO: 6, vector and host cell line comprising the nucleotide. The present disclosure also relates to an antibody that binds to extracellular region of human CD147, wherein the antibody comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO: 2, and/or a light chain variable region having the amino acid sequence of SEQ ID NO: 1, and the antibody contains a glycoform lacking both fucose residues and xylose residues, pharmaceutical composition comprising the antibody or fragment thereof, the method of producing the antibody or fragment thereof, and use of the pharmaceutical composition in treatment of CD147 expression-related diseases.

Abstract: The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (PMR) or Takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.

Abstract: TIM1 antagonists reduce GVHD by symptom score and show statistically significant improved survival.

Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.

Abstract: The present invention relates to antibodies or fragments thereof binding to human WT1/HLA. In particular, the present invention relates to antibodies or fragments thereof that have combined improved and/or beneficial properties, and are therefore suited for clinical development.

Abstract: The present disclosure relates to compositions and methods comprising peptide molecules that mimic the binding and functional properties of native antibodies relative to their respective targets. Some embodiments comprise peptide-drug conjugates (PDCs) comprising the mimic peptides disclosed herein. The targets of these mimic peptides include epidermal growth factor receptor (EGFR), and human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor (VEGF), programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1). The present disclosure comprises application of the knob-socket computational model to design antibody mimics for proteins.

Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.

Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.

Abstract: The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin.

Abstract: The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-Müllerian hormone type II receptor (AMHR-II) and an anticancer agent, as well as the therapeutic applications of these compositions.

Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.

Abstract: Methods for predicting a therapeutic response in a patient (e.g., a cancer patient) to ErbB3 inhibitors, and methods of treating a cancer patient with targeted therapies.

Abstract: The invention includes monoclonal and polyclonal antibodies, and antigen-binding fragments thereof, having specific binding affinity for 4,6-diamino-5-(formylamino)pyrimidine (FAPY-adenine); hybridomas producing such antibodies; immunoconjugates comprising an antibody or antigen-binding fragment of the invention coupled to a moiety; and in vitro and in vivo methods for using such antibodies, antibody fragments, and conjugates based on binding to FAPY-adenine; nucleic acids encoding the heavy and/or light chains of the antibodies; vectors comprising the nucleic acid sequences encoding the heavy and/or light chains; host cells comprising and, optionally, expressing the nucleic acid sequences; and methods for the production of the aforementioned materials.

Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.

Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.

Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.

Abstract: The present invention provides amic acids and imides derived from a polymer comprising: (a) maleic anhydride, (b) a first C1-C7 alkyl vinyl ether monomer, and (c) a second C8-C30 alkyl vinyl ether monomer, wherein the polymer contains an amic acid or an imide group. The polymers containing an amic acid or an imide group of the invention may be employed in a wide variety of compositions, particularly in oral care compositions. Non-limiting generic structures of the amidic polymers are set out below: (I) wherein R1-R3, M, a, b, c, d, e, and f are defined herein.

Abstract: A magnesium halide adduct represented by the formula (I): MgX2.mROH.nE.pH2O, in which X is chlorine, bromine, a C1-C12 alkoxy, a C3-C10 cycloalkoxy or a C6-C10 aryloxy, with the proviso that at least one X is chlorine or bromine; R is a C1-C12 alkyl, a C3-C10 cycloalkyl or a C6-C10 aryl; E is an o-alkoxybenzoate compound represented by the formula (II): in which R1 and R2 groups are independently a C1-C12 linear or branched alkyl, a C3-C10 cycloalkyl, a C6-C10 aryl, a C7-C10 alkaryl or an C7-C10 aralkyl, the R1 and R2 groups are identical to or different from the R group; m is in a range of from 1.0 to 5.0; n is in a range of from 0.001to 0.5; and p is in a range of from 0 to 0.8, is disclosed. A catalyst component useful in olefin polymerization, which comprises a reaction product of (1) the magnesium halide adduct, (2) a titanium compound, and optionally (3) an electron donor compound, is also disclosed.

Abstract: Propylene homopolymer having a melt flow rate MFR2 (230° C.) at least 50 g/10 min, a Mw/Mn at least 12.0 and a xylene cold soluble content (XCS) of at least 2.8 wt.-%.

Abstract: Ring-opening metathesis polymerization of apopinene and related functionalized monomers and corresponding polymer products.

Abstract: Propylene homopolymer having a melt flow rate MFR2 (230° C.) at least 50 g/10 min, a Mw/Mn at least 12.0 and a xylene cold soluble content (XCS) of at least 2.8 wt.-%.

Abstract: [Problem] To provide an ethylene-?-olefin copolymer that is highly effective in improving the molding properties of polyolefin resins, improving the balance between impact strength and stiffness, and improving transparency. [Solution] Provided is an ethylene-?-olefin copolymer having a specific MFR, a specific density, and a specific molecular weight distribution, containing a suitable amount of a long-chain branching structure characterized by a branching index, and having a specific composition distribution structure characterized by solvent fractionation behavior.

Abstract: [Problem] To provide an ethylene-?-olefin copolymer that is highly effective in improving the molding properties of polyolefin resins and at the same time highly effective improving the balance between impact strength and stiffness. [Solution] Provided is an ethylene-?-olefin copolymer having a specific MFR, a specific density, and a specific molecular weight distribution, containing a suitable amount of a long-chain branching structure characterized by a branching index, and having a specific composition distribution structure characterized by solvent fractionation behavior.

Abstract: The present invention provides an olefin resin with an improved heat resistance, reduced stickiness, excellent optical and low temperature properties, as well as the balance between these physical properties. The olefin resin according to the present invention satisfies the following requirements: (I) a melting peak (Tm) is observed within the range of from 60° C. to 130° C., and the heat of fusion ?H at the melting peak is within the range of from 5 to 150 J/g; (II) the percentage E (wt %) of a portion soluble in o-dichlorobenzene at 20° C. or lower, and the heat of fusion ?H satisfy certain relationships; (III) the glass transition temperature (Tg) is from ?80 to ?30° C.

Abstract: The instant invention provides a procatalyst comprising a metal-ligand complex of Formula (I): (Formula I), wherein M, X, n, each Z, L, R21, R22 and R1 through R20 are each described herein.

Abstract: The invention provides a process to form an olefin-based polymer, said process comprising polymerizing at least one olefin in the presence of at least one catalyst system comprising the reaction product of the following: A) at least one cocatalyst; and B) a procatalyst comprising a metal-ligand complex of Formula (I), as described herein: (Formula I).

Abstract: The invention provides an ethylene-based polymer comprising the following properties: a) a ZSVR value from 1.2 to 2.6, b) a MWD from 1.5 to 2.8, and c) a tan delta (0.1 rad/s; 190 C) from 5.0 to 50.

Abstract: A copolymer includes (i) a plurality of ethylenic moieties A having a structure according to the following formula: wherein R2 and R3 independently represent hydrogen, a halogen or an optionally substituted linear, branched or cyclic alk(en)yl group, or an optionally substituted aromatic or heteroaromatic group, and (ii) a plurality of acetal moieties B having a structure according to the following formula: wherein L represents a divalent linking group; x=0 or 1 and R1 represents an optionally substituted aromatic or heteroaromatic group including at least one hydroxyl group and optionally one or more additional substituent(s), and at least one electron withdrawing group in ortho or para position relative to the at least one hydroxyl group.

Abstract: To provide an inhibitor for inhibiting protein adhesion capable of easily forming a coating layer which is excellent in water resistance, from which coating components are less likely to be eluted, on which protein is less likely to be adsorbed and which is excellent in biocompatibility; a coating solution; a medical device having a coating layer employing this inhibitor for inhibiting protein adhesion; a method for producing the same; and a fluoropolymer to be used in this inhibitor for inhibiting protein adhesion. A compound for inhibiting protein adhesion comprising a fluoropolymer that has units having a biocompatible group, a fluorine atom content of from 5 to 60 mass % and a proportion P represented by the following formula of from 0.1 to 4.5%. (Proportion P)=((proportion (mass %) of units having a biocompatible group to all units of the fluoropolymer))/(fluorine atom content (mass %) of the fluoropolymer))×100.

Abstract: A nitrile copolymer rubber composition including a nitrile copolymer rubber (A) containing 35 to 80 wt % of ?,?-ethylenically unsaturated nitrile monomer units (a1), 19.5 to 64.5 wt % of conjugated diene monomer units (a2), and 0.5 to 20 wt % of ?,?-ethylenically unsaturated carboxylic acid monomer units (a3) and an inorganic filler (B) with an aspect ratio of 30 to 2,000, wherein a content of the inorganic filler (B) with respect to 100 parts by weight of the nitrile copolymer rubber (A) is 1 to 200 parts by weight is provided.

Abstract: There is provided a crumb of a block copolymer, which is excellent in transportability and, when used for a pressure-sensitive adhesive composition, is capable of forming a pressure-sensitive adhesive composition excellent in solubility, the low-melt viscosity property, the low-odor property, and the balance among these properties. The present invention relates to a crumb of a block copolymer, comprising at least one polymer block comprising a vinyl aromatic hydrocarbon monomer unit as a primary component and at least one polymer block comprising a conjugated diene compound monomer unit as a primary component, having a weight-average molecular weight of 20,000 to 1,000,000, and having a specific surface area, a cumulative pore volume of pores having a pore radius of 1 ?m to 100 ?m, and an average pore radius that are in respective predetermined ranges.

Abstract: A multiblock copolymer, obtainable by copolymerization of a conjugated diene compound and a non-conjugated olefin, wherein: a structure of the multiblock copolymer includes A-(B-A)x and/or B-(A-B)x, wherein “A” represents a block portion constituted of monomer units of a non-conjugated olefin, “B” represents a block portion constituted of monomer units of a conjugated diene compound, and “x” represents an integer ?1; content of the non-conjugated olefin portion is ?30 mass %; and storage modulus G? at 130° C., measured by rubber process analysis using a rubber process analyzer, i.e. RPA, according to ASTM D6204, is ?20 kPa. It is possible to obtain vulcanized rubber and thus a tire having high fracture resistance and high weather resistance from the multiblock copolymer and a rubber composition derived therefrom.

Abstract: The present disclosure relates to pyrrolidine-based catalysts for use in a polyurethane formulation. The polyurethane formulation includes the pyrrolidine-based catalyst, a compound containing an isocyanate functional group, an active hydrogen-containing compound. The use of such catalysts produces high quality polyurethane foam while reducing environmental concerns that can arise during the production of polyurethane foam as well as in in the foam that is produced.

Abstract: A reaction system for forming a thermoset urethane or polyurethane comprising at least one polyol, at least one isocyanate, and a zinc-containing catalyst. In some aspects, the polyol may be a monomeric polyol comprising secondary hydroxyl groups or it may be a polymeric polyol comprising residues of the monomeric polyol. The zinc-containing catalyst may be effective for catalyzing the reaction of the polyol and isocyanate, particularly when at least a portion of the secondary hydroxyl groups in the monomeric or polymeric polyol are hindered secondary hydroxyl groups. Urethanes and polyurethanes formed as described herein may be used in coating compositions, including powder coating compositions, solvent-based coating compositions, and waterborne coating compositions, as well as in many other applications.

Abstract: Methods and formulations for distortional thermosets are disclosed that display enhanced composite mechanical performances and robust sorption resistance. The composition includes an epoxy resin of formula (I): and a diamine curing agent. The resultant distortional thermoset compositions possess superior out-life requirements and advantageous reaction kinetics for preparing prepreg compositions and materials.

Abstract: The present invention is characterized by introducing isosorbide to a monomer configuration for securing the transparency of a biodegradable polymer as well as providing material having excellent heat resistance and flexibility, As a monomer, a component derived from isosorbide which has a rigid structure is contained by 10-50 mol % of a total diol component, thereby bringing a heat resistance enhancing effect, and enhancing transparency by interfering with crystal formation, and allowing for providing a polymer having excellent flexibility. Thus, the present invention may enable securing stability in usage especially in the packaging area, and enable the heightening of the range of usage and utilization thereof.

Abstract: The present invention provides alkoxylated polymers. The alkoxylated polymers have two or more alkoxylated sites. The alkoxylated polymers can comprise any monomers and/or oligomers that contain one or more functional groups with an active hydrogen. The alkoxylated polymers are useful in any application for which polymers are generally used. For example, the alkoxylated polymers are useful as additives in ink and coating compositions.

Abstract: Alkylene oxide polymerizations are performed in the presence of a double metal cyanide polymerization catalyst and certain magnesium, Group 3-Group 15 metal or lanthanide series metal compounds. The presence of the magnesium, Group 3-Group 15 metal or lanthanide series metal compound provides several benefits including more rapid catalyst activation, faster polymerization rates and the reduction in the amount of ultra high molecular weight polymers that are formed. The catalyst mixture is unexpectedly useful in making polyethers having low equivalent weights.

Abstract: The present invention relates to a phosphinated poly(2,6-dimethy phenylene oxide)oligomer, specifically an unsaturated group-containing phosphinated poly(2,6-dimethy phenylene oxide)oligomer, and processes for producing the same. A thermoset produced from the unsaturated group-containing phosphinated poly(2,6-dimethy phenylene oxide)oligomers according to the present invention exhibits flame retardancy and has a low dielectric constant and dissipation factor and a high glass transition temperature.

Abstract: A flow reactor system and methods having tubing useful as polymerization chamber. The flow reactor has at least one inlet and at least one mixing chamber, and an outlet. The method includes providing two phases, an aqueous phase and a non-aqueous phase and forming an emulsion for introduction into the flow reactor.

Abstract: A poly(imide-amide) copolymer includes: an imide structural unit which is a reaction product of a first diamine and a dianhydride, and an amide structural unit which is a reaction product of a second diamine and a diacyl halide, wherein each of the first diamine and the second diamine includes 2,2?-bis-trifluoromethyl-4,4?-biphenyldiamine, and at least one of the first diamine and the second diamine further includes a compound represented by Chemical Formula 1, wherein the dianhydride includes 3,3?,4,4?-biphenyltetracarboxylic dianhydride and 4,4?-hexafluoroisopropylidene diphthalic anhydride, wherein the diacyl halide includes terephthaloyl chloride (TPCI), and wherein an amount of the compound represented by Chemical Formula 1 is less than or equal to about 10 mole percent based on the total amount of the first diamine and the second diamine: NH2-A-NH2??Chemical Formula 1 wherein in Chemical Formula 1, A is the same as described in the detailed description.

Abstract: Methods and formulations for modified silicone resins of Formula (II) are presented. Formula (II) comprises at least one of each of the following subunits: The R1, R2, R3, R6, R7, R8, R9, R10, R11, R12 and R13 are each independently selected from a group consisting of H, alkyl, alkenyl, alkynyl, and aryl. The X is selected from a group consisting of arylene, transition metal, inorganic oxide, and silsesquioxane. The values of t ranges from 1 to 10, y ranges from 1 to 200 and z ranges from 1 to 1,000. The elastomeric materials prepared from modified silicone resins display robust mechanical properties following prolonged exposure to high temperatures (e.g., 316° C. or higher).

Abstract: Curable silsesquioxane polymers are described comprising a core comprising a first silsesquioxane polymer and an outer layer comprising a second silsesquioxane polymer bonded to the core. The silsesquioxane polymer of the core, outer layer, or combination thereof comprises ethylenically unsaturated groups. The first silsesquioxane polymer of the core is bonded to the second silsesquioxane polymer of the outer layer via silicon atoms bonded to three oxygen atoms. In some embodiments, the outer layer has a higher concentration of ethylenically unsaturated groups than the core. In this embodiment, the core may be substantially free of ethylenically unsaturated groups. In other embodiments, the core has a higher concentration of ethylenically unsaturated groups than the core. In this embodiment, the outer layer may be substantially free of ethylenically unsaturated groups. The core and outer layer each comprise a three-dimensional branched network of a different silsesquioxane polymer.

Abstract: The present invention is directed to plant fiber-reinforced thermoplastic compositions and a method for reinforcing thermoplastic resins. The present invention provides a use for the cellulose portion of a plant material, which is the portion left over after processing the selected plant materials to separate the hemi-cellulose and lignin from the cellulose.

Abstract: Analyte-insensitive materials comprising polymerizable monomers suitable for use in forming a hydrophilic, cross-linked gel comprising on the surface of a substrate for an electrode.

Abstract: The present invention relates to a method for manufacturing coagulated particles from a latex prepared by emulsion polymerization, containing step of discharging the latex prepared by emulsion polymerization containing a thickener or the latex prepared by emulsion polymerization having a given viscosity into a solution containing a coagulating agent, to coagulate the latex prepared by emulsion polymerization, aggregates having an anisotropy shape obtained by discharging a latex prepared by emulsion polymerization containing a thickener into a solution containing a coagulating agent, and coagulated particles from the latex prepared by emulsion polymerization obtained by the method.

Abstract: Provided are a nanostructure and an optical device including the nanostructure. The nanostructure is formed on a two-dimensional material layer such as graphene and includes nanopatterns having different shapes. The nanopatterns may include a first nanopattern and a second nanopattern and may be spherical; cube-shaped; or poly-pyramid-shaped, including a triangular pyramid shape; or polygonal pillar-shaped.